Delorazepam

Delorazepam is a benzodiazepine which, like other drugs in its class, possesses anxiolytic, skeletal muscle relaxant, hypnotic and anticonvulsant properties. It may have adverse effects including drowsiness, and cognitive impairments including short term memory impairment. Delorazepam is an active metabolite of the benzodiazepine known as cloxazolam. It is a long acting benzodiazepine which makes it superior in this sense to lorazepam that is short acting. Lorazepam is also a major active metabolite of delorazepam. In addition to be long acting, delorazepam is relatively potent, with 1 mg of delorazepam being the equivalent of 10 mg diazepam. It has received approval for marketing in Italy. Delorazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance. It is grouped under the following drug class(es): Benzodiazepines and Schedule IV controlled substances. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Chlordemethyldiazepam, Dadumir, Aurazepam and Briantum. It is listed as a controlled drug substance (Schedule IV). Its PubChem CID is 17925.